Edition:
United States

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

55.05USD
14 Dec 2017
Change (% chg)

$-1.58 (-2.79%)
Prev Close
$56.63
Open
$56.54
Day's High
$57.79
Day's Low
$54.72
Volume
487,844
Avg. Vol
606,768
52-wk High
$57.79
52-wk Low
$11.42

Latest Key Developments (Source: Significant Developments)

Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement
7:55am EST 

Dec 15 (Reuters) - Nektar Therapeutics ::NEKTAR THERAPEUTICS - ‍ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007​.  Full Article

Nektar Therapeutics Says Received Notice Of Termination From Daiichi Of Collaboration Agreement
Tuesday, 12 Dec 2017 04:15pm EST 

Dec 12 (Reuters) - Nektar Therapeutics ::NEKTAR THERAPEUTICS - ON DEC 6, CO RECEIVED NOTICE OF TERMINATION FROM DAIICHI OF COLLABORATION AGREEMENT WHICH WILL BECOME EFFECTIVE AS OF FEB 4, 2018.NEKTAR THERAPEUTICS - CO WILL PAY TO DAIICHI A $12.5 MILLION TERMINATION PAYMENT AND ALL RIGHTS AND LICENSES GRANTED TO DAIICHI UNDER AGREEMENT.NEKTAR THERAPEUTICS - TERMINATION PAYMENT DOES NOT CHANGE CO'S S 2017 FINANCIAL GUIDANCE, WHICH WAS PROVIDED IN FINANCIAL RESULTS ON NOV 7.  Full Article

Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program
Friday, 24 Nov 2017 06:21am EST 

Nov 24 (Reuters) - Nektar Therapeutics :Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs.Nektar Therapeutics - costs related to concluding co’s activities related to Bayer's phase 3 Amikacin Inhale clinical program under 2007 agreement.Nektar Therapeutics - based on discussion with Bayer, Nektar does not expect Bayer to move forward any further with the Amikacin Inhale program.  Full Article

EMA recommends against approval after re-examination of Nektar's drug onzeald
Friday, 10 Nov 2017 07:37am EST 

Nov 10 (Reuters) - EU Medicines Agency::EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN‍​.  Full Article

Nektar Therapeutics reports Q3 earnings per share $0.39
Tuesday, 7 Nov 2017 04:10pm EST 

Nov 7 (Reuters) - Nektar Therapeutics ::Nektar Therapeutics reports financial results for the third quarter of 2017.Q3 earnings per share $0.39.Q3 revenue $152.9 million versus $36.3 million.Q3 revenue view $114.6 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.17 -- Thomson Reuters I/B/E/S.  Full Article

Nektar Therapeutics Q2 loss per share $0.39
Tuesday, 8 Aug 2017 04:10pm EDT 

Aug 8 (Reuters) - Nektar Therapeutics :Nektar therapeutics reports financial results for the second quarter of 2017.Q2 loss per share $0.39.Q2 revenue $34.6 million versus i/b/e/s view $34.2 million.Q2 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

Eli Lilly and Nektar Therapeutics to develop, commercialize NKTR-358
Monday, 24 Jul 2017 07:30am EDT 

July 24 (Reuters) - Eli Lilly and Co ::Lilly and Nektar Therapeutics announce alliance to develop and commercialize NKTR-358, an autoimmune therapy.Says Nektar will get initial payment of $150 million, is eligible for up to $250 million additional development & regulatory milestones.Says co, Nektar to co-develop NKTR-358 with Nektar responsible for completing Phase 1 clinical development.Says co, Nektar will share Phase 2 development costs 75 percent Lilly and 25 percent Nektar.Says Nektar will have option to participate in Phase 3 development on an indication-by-indication basis for NKTR-358.Co to be responsible for all costs of global commercialization for NKTR-358; Nektar to have option to co-promote in U.S. under some conditions.Says subject to closing of deal, co expects to incur acquired in-process research and development charge to earnings in 2017 of about $0.09 per share.Says there will be no change to co's 2017 non-GAAP earnings per share guidance as a result of Nektar transaction.FY2017 earnings per share view $4.12 -- Thomson Reuters I/B/E/S.  Full Article

Nektar Therapeutics reports Q1 revenue $24.7 million
Tuesday, 9 May 2017 04:10pm EDT 

May 9 (Reuters) - Nektar Therapeutics :Nektar Therapeutics reports financial results for the first quarter of 2017.Q1 loss per share $0.42.Q1 revenue $24.7 million versus I/B/E/S view $26.8 million.Q1 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

Nektar Therapeutics says NKTR-181 meets primary, secondary endpoints in Phase 3 summit-07 study in chronic pain
Monday, 20 Mar 2017 07:30am EDT 

Nektar Therapeutics : Nektar Therapeutics says NKTR-181, an opioid analgesic, meets primary and secondary endpoints in phase 3 summit-07 study in chronic pain . Nektar therapeutics says NKTR-181 significantly reduced pain in patients with moderate to severe chronic low back pain .FDA has granted investigational NKTR-181 fast track designation for the treatment of moderate to severe chronic pain.  Full Article

Nektar Therapeutics Q4 loss per share $0.28
Wednesday, 1 Mar 2017 04:10pm EST 

Nektar Therapeutics : Nektar Therapeutics reports fourth quarter and year-end 2016 financial results . Q4 loss per share $0.28 . Q4 revenue $37.5 million versus I/B/E/S view $40.7 million .Q4 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement

* NEKTAR THERAPEUTICS - ‍ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007​ Source text: (http://bit.ly/2BsgSdG) Further company coverage: